December 22, 2015

Ossining’s Intel Finalist Looks to Impact Cancer Research

The first ever Intel finalist for Ossining HS, Daniel McQuaid, is studying a cancer-supressing protein. Ossining High School’s Daniel McQuaid has turned a devastating experience into a positive contribution. “In my freshman year of high school, my cousin died of lung cancer, so that kind of sparked my interest in the […]
Do you like it?0
Read more
December 22, 2015

Department of Medicine interview with Goutham Narla, MD

Goutham Narla, MD, Pardee-Gerstacker Professor in Cancer Research, talks about the challenging process of drug development, shares how his background in economics helps him succeed in his research career and discusses the importance of building strong mentoring relationships. Your research in cancer has generated great momentum and gathered attention from the […]
Do you like it?0
Read more
May 20, 2014

Discovery of Apparent Key Driver in Spread of Ovarian Cancer

After a dozen years of searching, Analisa DiFeo, PhD, and her team have discovered what appears to be one of the key drivers in the spread of ovarian cancer. The culprit is a biomarker, which can signal the presence of a disease. In this instance, however, the biomarker known as […]
Do you like it?0
Read more
November 12, 2013

Dr. Goutham Narla helps form Dual Therapeutics to focus drug development on prostate cancer, lung cancer, and acute lymphoblastic leukemia.

BioMotiv, a drug development accelerator based in Cleveland, and the Icahn School of Medicine at Mount Sinai, based in New York, are announcing the formation of Dual Therapeutics, a company focused on producing therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Dual Therapeutics is based on intellectual property […]
Do you like it?0
Read more
November 6, 2013

Dr. Goutham Narla helps in Drug development for prostate cancer, lung cancer and acute lymphoblastic leukemia

A $250 million drug discovery initiative launched last year at University Hospitals of Cleveland has produced its second startup, this one based on cancer research from the Icahn School of Medicine at Mount Sinai. Dual Therapeutics will develop new treatments for prostate cancer, lung cancer and acute lymphoblastic leukemia, according to an […]
Do you like it?0
Read more
May 18, 2013

Dr. Goutham Narla to Receive Individual Award in Advancements in Healthcare Category from Crain’s Cleveland Business

Crain’s is proud to honor these dedicated heroes for their achievements and outstanding level of care that enriches everyday life. Awards Luncheon: Tuesday, May 21 •  1:00am-1:30pm 2013 Health Care Heroes Award Recipients Administrator  of the Year •  Nursing: Catherine Koppelman, Chief Nursing  Officer; University Hospitals •  Hospital:  Cynthia Moore-Hardy, […]
Do you like it?0
Read more
May 18, 2013

Dr. Goutham Narla Discovers a Novel Drug Combination to Treat Advanced Lung Cancer

Dr. Goutham Narla and his team have found that by using a combination of two FDA approved drugs – Erlotinib and Trifluoperazine – a process that is causing lung tumor cells to die can be initiated. A team of researchers led by Dr. Goutham Narla at Case Western Reserve University […]
Do you like it?0
Read more
June 3, 2012

Hope For Late-Stage Lung Cancer? Two-Drug Combo Activates Genes That Help Tumors Self-Destruct

A schizophrenia treatment might be the special ingredient in a one-two punch to combat late-stage lung cancer. Researchers from Case Western Reserve University School of Medicine and Mount Sinai School of Medicine found that the anti-psychotic medication trifluoperazine can reactivate a gene pathway involved in tumor suppression that’s normally turned […]
Do you like it?0
Read more